Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia
Amanda Winters(University of Colorado Denver), Daniel A. Pollyea(University of Colorado Denver), Molly Nakic(University of Colorado Hospital), Keri Halsema(University of Colorado Anschutz Medical Campus), Chelsey Boggs(University of Colorado Anschutz Medical Campus), Stephanie Chase(Eastern Oregon University), Jeff Kaiser, Craig T. Jordan(University of Colorado Anschutz Medical Campus), Jonathan A. Gutman(University of Colorado Denver), Julie Rosser(University of Colorado Denver), Brett M. Stevens(University of Colorado Anschutz Medical Campus), Steven R. Schuster(University of Colorado Hospital), Mark D. Ewalt(University of Colorado Denver), Jeffrey Schowinsky(University of Colorado Denver), Lindsey Lyle(University of Colorado Anschutz Medical Campus), Clayton A. Smith(University of Colorado Anschutz Medical Campus), Vishal Rana(University of Colorado Hospital), Diana Abbott(University of Colorado Anschutz Medical Campus), Bradford Siegele(Children's Hospital Colorado), Jennifer Tobin, Enkhtsetseg Purev(University of Colorado Denver)
Cited by 147
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Human occupation of northern Australia by 65,000 years ago
|Nature|2017|1.2k
The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells
|Blood|2005|675
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655